August 2000 by Michael Marco and Jeffrey Schouten The CDC should further investigate the role of HCV sexual transmission in men who have sex with men. The CDC should update its 1998 HCV recommendations to suggest HCV testing for all…
Progress Is Being Made But Much Remains to Be Done in the Treatment of Hepatitis C Infection June 2000 Sexual Transmission Controversy Michael Marco, TAG's Infections and Oncology Project Director, had his plate full in San Francisco this past February…
Merck’s Cavalier Attitude Toward the Welfare of HIV/HCV-Coinfected Patients by Tracy Swan In places where access to antiretroviral therapy is widespread, people living with HIV are now dying from a common and curable coinfection: hepatitis C virus (HCV). HIV increases…
TAG at 20: Early Campaigns; The Odyssey of Therapeutic Vaccines for HIV; What You Don’t Know, You Can Sell; Does Obama’s 2013 Budget Herald the End of PEPFAR?; Childhood TB Advocacy Picks Up Steam
The Hepatitis C Community Advisory Board (HCAB) recognizes the value of more effective and less toxic treatment for hepatitis C virus (HCV).
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
By Coco Jervis and Sue Perez Negligible Increases for AIDS, TB, Viral Hepatitis Treatment and Research On Monday, February 1, 2010, President Barack Obama unveiled his fiscal year (FY) 2011 budget to the U.S. Congress. Global health programs were allocated…
By Tracy Swan and Lei Chou Background: In the United States, the highest all-cause mortality rates are found among African American men and women aged 25 to 64. This racial disparity is underscored by a disproportionate burden of viral hepatitis…
HIV, Hepatitis C Virus (HCV), and Tuberculosis Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development Second Edition September 2011 Written by Polly Clayden, Simon Collins, Mark Harrington, Richard Jefferys, Tracy Swan, Javid Syed, and Claire Wingfield with a a contribution…